Harry Welten

Biography

 Dr. Harry Welten, MBA, has been Chief Financial Officer of Kuros Biosciences AG since JUne 2010. Dr. Welten serves as Chief Financial Officer of Kuros Biosciences AG. He served as Chief Financial Officer and Executive Vice President of Cytos Biotechnology AG since August 2010 and as its Member of Executive Board since August 29, 2011. He served as Chief Financial Officer at Nitec Pharma AG in Reinach, Switzerland, which merged with US-based Horizon Pharma Inc. and was listed on Nasdaq in 2011. He has 20 years of international executive experience, more than 11 of which as a CFO in the biotech industry. Dr. Welten served as Chief Financial Officer of Arpida AG since August 2001 until 2009 and also as its Senior Vice President. Prior to joining Arpida, he held various senior management positions at UBS group including Director at UBS Warburg in New York. Before joining UBS, Mr. Welten was with ABB and DaimlerChrysler. He has been Chairman of the Board of Biognosys AG since February 26, 2016. He serves as Director of Kuros Biosciences AG. He serves as a Director of Kanyos Bio, Inc., Anokion SA. He has been Director at Kuros Biosciences AG since 2016. He has been a Director of Biognosys AG since 2011 and Biotie Therapies AG since January 2009. He serves as a member of the Board of Directors of ProteoMediX AG, Horizon Pharma AG and BioSupport AG. He is a member of the foundation council of HBM Foundation. He holds a degree in banking and finance, a degree in economics and business administration and an MBA (Hons) from Columbia University, NY, USA.

Research Interest

 Banking and finance business administration